Your browser is no longer supported. Please, upgrade your browser.
Settings
ARCT [NASD]
Arcturus Therapeutics Holdings Inc.
Index- P/E- EPS (ttm)-4.86 Insider Own3.50% Shs Outstand26.24M Perf Week-3.67%
Market Cap853.77M Forward P/E7.14 EPS next Y4.60 Insider Trans-4.21% Shs Float21.59M Perf Month14.26%
Income-118.70M PEG- EPS next Q-2.14 Inst Own70.80% Short Float23.21% Perf Quarter-36.04%
Sales9.00M P/S94.86 EPS this Y-65.00% Inst Trans-5.63% Short Ratio9.11 Perf Half Y-69.45%
Book/sh13.44 P/B2.44 EPS next Y163.80% ROA-33.20% Target Price- Perf Year-10.81%
Cash/sh17.96 P/C1.83 EPS next 5Y- ROE-43.00% 52W Range24.87 - 129.71 Perf YTD-24.27%
Dividend- P/FCF- EPS past 5Y10.80% ROI- 52W High-74.10% Beta2.77
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low35.10% ATR2.08
Employees118 Current Ratio8.80 Sales Q/Q-19.20% Oper. Margin- RSI (14)53.87 Volatility5.95% 6.19%
OptionableYes Debt/Eq0.17 EPS Q/Q-218.90% Profit Margin- Rel Volume0.45 Prev Close32.85
ShortableYes LT Debt/Eq0.16 EarningsMay 10 AMC Payout- Avg Volume550.06K Price33.60
Recom2.40 SMA207.85% SMA500.68% SMA200-37.04% Volume223,226 Change2.28%
Jun-04-21Resumed Robert W. Baird Neutral $31
Feb-17-21Downgrade B. Riley Securities Neutral → Sell
Jan-19-21Downgrade B. Riley Securities Buy → Neutral $138 → $77
Jan-15-21Downgrade B. Riley Securities Buy → Neutral $138 → $77
Jan-07-21Initiated Wells Fargo Overweight $118
Dec-29-20Downgrade Robert W. Baird Outperform → Neutral $79 → $69
Dec-29-20Downgrade Raymond James Outperform → Mkt Perform
Dec-29-20Downgrade H.C. Wainwright Buy → Neutral
Dec-29-20Downgrade Barclays Overweight → Equal Weight $46
Dec-23-20Downgrade ROTH Capital Buy → Sell $77
Dec-08-20Reiterated B. Riley Securities Buy $111 → $138
Dec-07-20Reiterated B. Riley Securities Buy $64 → $111
Oct-26-20Initiated Barclays Overweight $72
Oct-06-20Initiated Citigroup Buy $65
Aug-26-20Initiated Piper Sandler Overweight $77
Jul-30-20Resumed ROTH Capital Buy $77
Jul-16-20Initiated Raymond James Outperform $72
Jul-13-20Initiated B. Riley FBR Buy
Jun-09-20Downgrade WBB Securities Buy → Hold
Feb-11-20Initiated Robert W. Baird Outperform $24
Jun-09-21 09:00AM  
Jun-02-21 09:01AM  
May-21-21 02:24AM  
May-13-21 06:10AM  
May-10-21 08:05PM  
04:01PM  
02:30PM  
May-03-21 08:30AM  
Apr-29-21 05:02PM  
Apr-14-21 01:36AM  
Apr-05-21 06:15AM  
Mar-30-21 08:30AM  
Mar-09-21 06:35AM  
Mar-01-21 05:26PM  
04:01PM  
02:30PM  
Feb-28-21 02:14AM  
Feb-22-21 08:00AM  
Feb-19-21 08:00AM  
Feb-11-21 08:30AM  
Jan-28-21 08:30AM  
Jan-23-21 04:40AM  
Jan-12-21 06:51AM  
Jan-07-21 03:19PM  
Jan-06-21 03:59PM  
11:14AM  
08:00AM  
Jan-05-21 08:57AM  
07:27AM  
Jan-04-21 10:18AM  
07:22AM  
07:01AM  
Dec-31-20 07:32PM  
08:49AM  
Dec-30-20 12:34PM  
11:40AM  
11:22AM  
07:00AM  
Dec-29-20 11:02PM  
05:35PM  
05:11PM  
04:33PM  
04:23PM  
03:27PM  
11:42AM  
10:23AM  
09:59AM  
09:49AM  
08:09AM  
Dec-28-20 04:01PM  
Dec-23-20 11:23AM  
Dec-20-20 06:09AM  
Dec-19-20 10:10PM  
Dec-16-20 06:14AM  
Dec-13-20 02:02PM  
06:05AM  
Dec-12-20 07:03AM  
Dec-11-20 02:38PM  
06:45AM  
Dec-10-20 06:10AM  
Dec-08-20 06:20PM  
Dec-07-20 11:30PM  
11:18PM  
04:33PM  
07:00AM  
Dec-05-20 06:12AM  
Nov-30-20 06:00PM  
Nov-23-20 08:40AM  
Nov-17-20 06:04AM  
Nov-16-20 09:30AM  
Nov-11-20 05:16AM  
Nov-10-20 03:46PM  
08:31AM  
Nov-09-20 11:10PM  
05:15PM  
04:01PM  
02:30PM  
07:00AM  
Nov-04-20 08:00AM  
Nov-02-20 04:33PM  
Oct-31-20 06:08AM  
Oct-30-20 02:40PM  
09:00AM  
Oct-29-20 12:34PM  
07:21AM  
Oct-08-20 10:06AM  
Oct-05-20 09:50AM  
08:00AM  
Oct-01-20 08:00AM  
Sep-29-20 06:42AM  
Sep-18-20 12:15PM  
Sep-17-20 01:12PM  
Sep-08-20 08:30AM  
Sep-04-20 10:31AM  
Sep-03-20 08:40AM  
Aug-31-20 06:12PM  
Aug-30-20 10:09AM  
Aug-23-20 09:02AM  
Aug-18-20 09:00AM  
Aug-11-20 08:00AM  
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG to develop mRNA therapeutic and vaccine candidates; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chivukula PadChief Scientific Officer & COOApr 01Sale42.9510,000429,500652,548Apr 05 04:30 PM
Chivukula PadChief Scientific Officer & COOMar 01Sale54.2310,000542,300662,548Mar 03 04:30 PM
Chivukula PadChief Scientific Officer & COOFeb 01Sale75.3110,000753,100672,548Feb 03 04:45 PM
Chivukula PadChief Scientific Officer & COOJan 04Sale46.4010,000464,000682,548Jan 05 06:19 PM
Ultragenyx Pharmaceutical Inc.DirectorDec 09Sale94.97357,74533,975,0432,200,000Dec 10 04:55 PM
Ultragenyx Pharmaceutical Inc.DirectorDec 08Sale105.54442,25546,675,5932,557,745Dec 10 04:55 PM
Chivukula PadChief Scientific Officer & COODec 01Sale96.1910,000961,900692,548Dec 03 05:45 PM
Chivukula PadChief Scientific Officer & COONov 02Sale55.2810,000552,800702,548Nov 03 08:01 PM
Chivukula PadChief Scientific Officer & COOOct 01Sale42.8310,000428,300712,548Oct 02 05:00 PM
Chivukula PadChief Scientific Officer & COOSep 03Sale45.1610,000451,600722,548Sep 04 05:05 PM